These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16565234)

  • 21. Renal manifestations in the metabolic syndrome.
    Locatelli F; Pozzoni P; Del Vecchio L
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S81-5. PubMed ID: 16565254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.
    Haffner SM; Ruilope L; Dahlöf B; Abadie E; Kupfer S; Zannad F
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):469-75. PubMed ID: 16633092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk.
    Smith SR
    Obesity (Silver Spring); 2006 Jun; 14 Suppl 3():128S-134S. PubMed ID: 16931494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antihypertensive agents and the risk of new onset diabetes mellitus].
    Kuzmanić D; Laganović M; Dika Z; Kos J; Pećin I
    Lijec Vjesn; 2006; 128(11-12):336-41. PubMed ID: 17212194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive agents and arterial stiffness: relevance to reducing cardiovascular risk in the chronic kidney disease patient.
    Agarwal R
    Curr Opin Nephrol Hypertens; 2007 Sep; 16(5):409-15. PubMed ID: 17693754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of appropriate patients for cardiometabolic risk management.
    Peters AL
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S9-16. PubMed ID: 17934394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
    de Simone G; Olsen MH; Wachtell K; Hille DA; Dahlöf B; Ibsen H; Kjeldsen SE; Lyle PA; Devereux RB
    J Hum Hypertens; 2007 Aug; 21(8):625-32. PubMed ID: 17476291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of antihypertensive drugs on glucose metabolism and cardiovascular events].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2009 Sep; 129(17):1740-4. PubMed ID: 19756054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome?
    Sarafidis PA; Lasaridis AN
    J Cardiometab Syndr; 2008; 3(3):183-7. PubMed ID: 18983337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular disease, metabolic syndrome and erectile dysfunction.
    Müller A; Mulhall JP
    Curr Opin Urol; 2006 Nov; 16(6):435-43. PubMed ID: 17053524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality.
    Klausen KP; Parving HH; Scharling H; Jensen JS
    J Intern Med; 2007 Oct; 262(4):470-8. PubMed ID: 17875184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic syndrome: a fata morgana?
    Bakker SJ; Gansevoort RT; de Zeeuw D
    Nephrol Dial Transplant; 2007 Jan; 22(1):15-20. PubMed ID: 17050636
    [No Abstract]   [Full Text] [Related]  

  • 33. Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease?
    de Zeeuw D; Bakker SJ
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S10-4. PubMed ID: 18580860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
    Meigs JB; Rutter MK; Sullivan LM; Fox CS; D'Agostino RB; Wilson PW
    Diabetes Care; 2007 May; 30(5):1219-25. PubMed ID: 17259468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time-dependent association between metabolic syndrome and risk of CKD in Korean men without hypertension or diabetes.
    Ryu S; Chang Y; Woo HY; Lee KB; Kim SG; Kim DI; Kim WS; Suh BS; Jeong C; Yoon K
    Am J Kidney Dis; 2009 Jan; 53(1):59-69. PubMed ID: 18838200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The metabolic syndrome in polycystic ovary syndrome.
    Essah PA; Wickham EP; Nestler JE
    Clin Obstet Gynecol; 2007 Mar; 50(1):205-25. PubMed ID: 17304037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M; Noberasco G; Re M; Filippi A; Gallina AM; Weiss U; Cannavò R; Ravera G; Cricelli C; Deferrari G
    Nephrol Dial Transplant; 2009 May; 24(5):1528-33. PubMed ID: 19073656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of pre-disease risk factors within metabolic syndrome on all-cause and cardiovascular disease mortality.
    Tsai SP; Wen CP; Chan HT; Chiang PH; Tsai MK; Cheng TY
    Diabetes Res Clin Pract; 2008 Oct; 82(1):148-56. PubMed ID: 18757109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.